ID

35188

Description

A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02361086

Lien

https://clinicaltrials.gov/show/NCT02361086

Mots-clés

Versions (1)
  1. 22/02/2019 22/02/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

22 février 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Castration-resistant Prostate Cancer NCT02361086

Anglais

Eligibility Castration-resistant Prostate Cancer NCT02361086

1 Formulaires  
Criteria
Description

Criteria

patients must have documented histological or cytological evidence of adenocarcinoma of the prostate.
Description

Adenocarcinoma of prostate

Type de données

boolean

Alias
UMLS CUI [1]
C0007112
patients must have a minimum serum psa level of >2 ng/ml that is rising based on the prostate cancer working group 2 criteria.
Description

Serum Prostate Specific Antigen Increased

Type de données

boolean

Alias
UMLS CUI [1]
C1883014
patients must have castrate levels of testosterone (<50 ng/dl [1.74 nmol/l]).
Description

Testosterone measurement Castration Level

Type de données

boolean

Alias
UMLS CUI [1,1]
C0523912
UMLS CUI [1,2]
C0007344
UMLS CUI [1,3]
C0441889
patients must have undergone orchiectomy, or have been on lhrh agonists or antagonists, for at least 3 months prior to study entry. patients on lhrh agonists/antagonists must remain on these agents for the duration of the study.
Description

Orchiectomy | Luteinizing Hormone-releasing Hormone Agonist | LHRH antagonists

Type de données

boolean

Alias
UMLS CUI [1]
C0029189
UMLS CUI [2]
C1518041
UMLS CUI [3,1]
C0023610
UMLS CUI [3,2]
C0243076
patients must have an ecog performance score of 0 or 1.
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
key exclusion criteria:
Description

Exclusion Criteria Main

Type de données

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
patients who have received prior cytotoxic chemotherapy for castration-resistant prostate cancer unless enrolled in a previous chemotherapy cohort.
Description

Cytotoxic Chemotherapy Castration-Resistant Prostatic Cancer

Type de données

boolean

Alias
UMLS CUI [1,1]
C0677881
UMLS CUI [1,2]
C3658266
patients who have received second-line antihormonal therapy, including ketoconazole, aminoglutethimide, or high-dose estrogen within 30 days of study entry.
Description

Second line Antihormone Therapy | Ketoconazole | Aminoglutethimide | Estrogens High dose

Type de données

boolean

Alias
UMLS CUI [1,1]
C1710038
UMLS CUI [1,2]
C2986607
UMLS CUI [2]
C0022625
UMLS CUI [3]
C0002555
UMLS CUI [4,1]
C0014939
UMLS CUI [4,2]
C0444956
patients who have completed sipuleucel-t (provenge ®) treatment within 30 days of study entry.
Description

sipuleucel-T | Provenge

Type de données

boolean

Alias
UMLS CUI [1]
C1706668
UMLS CUI [2]
C1135133
patients who have received tok-001 (galeterone®) or any other investigational product directed towards the androgen receptor or androgen biosynthesis.
Description

TOK-001 | Galeterone | Investigational New Drugs Targeted Androgen Receptor | Investigational New Drugs Targeted Androgen biosynthesis

Type de données

boolean

Alias
UMLS CUI [1]
C2830126
UMLS CUI [2]
C1569219
UMLS CUI [3,1]
C0013230
UMLS CUI [3,2]
C1521840
UMLS CUI [3,3]
C0034786
UMLS CUI [4,1]
C0013230
UMLS CUI [4,2]
C1521840
UMLS CUI [4,3]
C1157302
patients who have received antiandrogens such as flutamide (eulexin®), bicalutamide (casodex®), or nilutamide (nilandron®) for > 3 months must be off treatment for 6 weeks and demonstrate a continued rise in psa after withdrawal. patients on antiandrogens for < 3 months must be off medication for 2 weeks. patients on 5 alpha reductase inhibitors such as finasteride (proscar®, propecia®), or dutasteride (avodart®) must stop medication at least 3 months from study entry.
Description

Androgen Antagonists | Flutamide | Eulexin | bicalutamide | Casodex | nilutamide | Nilandron | 5-alpha Reductase Inhibitors To be stopped | Finasteride | Proscar | Propecia | Dutasteride | Avodart

Type de données

boolean

Alias
UMLS CUI [1]
C0002842
UMLS CUI [2]
C0016384
UMLS CUI [3]
C0591412
UMLS CUI [4]
C0285590
UMLS CUI [5]
C0591237
UMLS CUI [6]
C0068771
UMLS CUI [7]
C0722107
UMLS CUI [8,1]
C2936788
UMLS CUI [8,2]
C1272691
UMLS CUI [9]
C0060389
UMLS CUI [10]
C0678149
UMLS CUI [11]
C0722858
UMLS CUI [12]
C0754659
UMLS CUI [13]
C1170079
patients who require pharmacological or replacement doses of systemic corticosteroids or who have received systemic corticosteroids within 30 days of study entry; use of topical, inhaled or ophthalmic steroids is permitted.
Description

CORTICOSTEROIDS FOR SYSTEMIC USE | Topical steroids allowed | Inhaled steroids allowed | Ophthalmic steroids allowed

Type de données

boolean

Alias
UMLS CUI [1]
C3653708
UMLS CUI [2,1]
C2064827
UMLS CUI [2,2]
C0683607
UMLS CUI [3,1]
C2065041
UMLS CUI [3,2]
C0683607
UMLS CUI [4,1]
C2013080
UMLS CUI [4,2]
C0683607
patients who have received palliative radiotherapy within 4 weeks of study entry.
Description

Palliative Radiation Therapy

Type de données

boolean

Alias
UMLS CUI [1]
C3898008
patients with a history within the last 3 years of another invasive malignancy.
Description

Cancer Other Invasive

Type de données

boolean

Alias
UMLS CUI [1,1]
C1707251
UMLS CUI [1,2]
C0205281
Retour au début de la page

Similar models

Eligibility Castration-resistant Prostate Cancer NCT02361086

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Adenocarcinoma of prostate
Item
patients must have documented histological or cytological evidence of adenocarcinoma of the prostate.
boolean
C0007112 (UMLS CUI [1])
Serum Prostate Specific Antigen Increased
Item
patients must have a minimum serum psa level of >2 ng/ml that is rising based on the prostate cancer working group 2 criteria.
boolean
C1883014 (UMLS CUI [1])
Testosterone measurement Castration Level
Item
patients must have castrate levels of testosterone (<50 ng/dl [1.74 nmol/l]).
boolean
C0523912 (UMLS CUI [1,1])
C0007344 (UMLS CUI [1,2])
C0441889 (UMLS CUI [1,3])
Orchiectomy | Luteinizing Hormone-releasing Hormone Agonist | LHRH antagonists
Item
patients must have undergone orchiectomy, or have been on lhrh agonists or antagonists, for at least 3 months prior to study entry. patients on lhrh agonists/antagonists must remain on these agents for the duration of the study.
boolean
C0029189 (UMLS CUI [1])
C1518041 (UMLS CUI [2])
C0023610 (UMLS CUI [3,1])
C0243076 (UMLS CUI [3,2])
ECOG performance status
Item
patients must have an ecog performance score of 0 or 1.
boolean
C1520224 (UMLS CUI [1])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Cytotoxic Chemotherapy Castration-Resistant Prostatic Cancer
Item
patients who have received prior cytotoxic chemotherapy for castration-resistant prostate cancer unless enrolled in a previous chemotherapy cohort.
boolean
C0677881 (UMLS CUI [1,1])
C3658266 (UMLS CUI [1,2])
Second line Antihormone Therapy | Ketoconazole | Aminoglutethimide | Estrogens High dose
Item
patients who have received second-line antihormonal therapy, including ketoconazole, aminoglutethimide, or high-dose estrogen within 30 days of study entry.
boolean
C1710038 (UMLS CUI [1,1])
C2986607 (UMLS CUI [1,2])
C0022625 (UMLS CUI [2])
C0002555 (UMLS CUI [3])
C0014939 (UMLS CUI [4,1])
C0444956 (UMLS CUI [4,2])
sipuleucel-T | Provenge
Item
patients who have completed sipuleucel-t (provenge ®) treatment within 30 days of study entry.
boolean
C1706668 (UMLS CUI [1])
C1135133 (UMLS CUI [2])
TOK-001 | Galeterone | Investigational New Drugs Targeted Androgen Receptor | Investigational New Drugs Targeted Androgen biosynthesis
Item
patients who have received tok-001 (galeterone®) or any other investigational product directed towards the androgen receptor or androgen biosynthesis.
boolean
C2830126 (UMLS CUI [1])
C1569219 (UMLS CUI [2])
C0013230 (UMLS CUI [3,1])
C1521840 (UMLS CUI [3,2])
C0034786 (UMLS CUI [3,3])
C0013230 (UMLS CUI [4,1])
C1521840 (UMLS CUI [4,2])
C1157302 (UMLS CUI [4,3])
Androgen Antagonists | Flutamide | Eulexin | bicalutamide | Casodex | nilutamide | Nilandron | 5-alpha Reductase Inhibitors To be stopped | Finasteride | Proscar | Propecia | Dutasteride | Avodart
Item
patients who have received antiandrogens such as flutamide (eulexin®), bicalutamide (casodex®), or nilutamide (nilandron®) for > 3 months must be off treatment for 6 weeks and demonstrate a continued rise in psa after withdrawal. patients on antiandrogens for < 3 months must be off medication for 2 weeks. patients on 5 alpha reductase inhibitors such as finasteride (proscar®, propecia®), or dutasteride (avodart®) must stop medication at least 3 months from study entry.
boolean
C0002842 (UMLS CUI [1])
C0016384 (UMLS CUI [2])
C0591412 (UMLS CUI [3])
C0285590 (UMLS CUI [4])
C0591237 (UMLS CUI [5])
C0068771 (UMLS CUI [6])
C0722107 (UMLS CUI [7])
C2936788 (UMLS CUI [8,1])
C1272691 (UMLS CUI [8,2])
C0060389 (UMLS CUI [9])
C0678149 (UMLS CUI [10])
C0722858 (UMLS CUI [11])
C0754659 (UMLS CUI [12])
C1170079 (UMLS CUI [13])
CORTICOSTEROIDS FOR SYSTEMIC USE | Topical steroids allowed | Inhaled steroids allowed | Ophthalmic steroids allowed
Item
patients who require pharmacological or replacement doses of systemic corticosteroids or who have received systemic corticosteroids within 30 days of study entry; use of topical, inhaled or ophthalmic steroids is permitted.
boolean
C3653708 (UMLS CUI [1])
C2064827 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
C2065041 (UMLS CUI [3,1])
C0683607 (UMLS CUI [3,2])
C2013080 (UMLS CUI [4,1])
C0683607 (UMLS CUI [4,2])
Palliative Radiation Therapy
Item
patients who have received palliative radiotherapy within 4 weeks of study entry.
boolean
C3898008 (UMLS CUI [1])
Cancer Other Invasive
Item
patients with a history within the last 3 years of another invasive malignancy.
boolean
C1707251 (UMLS CUI [1,1])
C0205281 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial